- Home
- ATYR vs CBUS Comparison
ATYR vs CBUS Comparison
Compare ATYR & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATYR | CBUS |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | 59 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 208.7M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | ATYR | CBUS |
|---|---|---|
| Price | $0.84 | $3.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 2 |
| Target Price | $4.20 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 1.4M | 548.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,262,000.00 |
| Revenue This Year | $9,628.95 | N/A |
| Revenue Next Year | $156.94 | $99.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 134.56 |
| 52 Week Low | $0.64 | $1.09 |
| 52 Week High | $7.29 | $4.19 |
Technical Indicators
Market Signals| Indicator | ATYR | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 62.16 |
| Support Level | $0.82 | $1.34 |
| Resistance Level | $0.85 | N/A |
| Average True Range (ATR) | 0.07 | 0.31 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 7.78 | 60.32 |
Price Performance
Historical ComparisonAbout ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.